×
KALA BIO SG&A Expenses 2016-2024 | KALA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
KALA BIO sg&a expenses from 2016 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
KALA BIO SG&A Expenses 2016-2024 | KALA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
KALA BIO sg&a expenses from 2016 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$129.4B
Gilead Sciences (GILD)
$121.9B
Bristol Myers Squibb (BMY)
$111B
CSL (CSLLY)
$91.9B
Regeneron Pharmaceuticals (REGN)
$90.6B
GSK (GSK)
$76B
Argenex SE (ARGX)
$35.4B
Alnylam Pharmaceuticals (ALNY)
$35.1B
BioNTech SE (BNTX)
$25.7B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$24.6B
BeiGene (BGNE)
$20.1B
Moderna (MRNA)
$19.3B
Incyte (INCY)
$15.9B
Genmab (GMAB)
$15.3B
Insmed (INSM)
$12.8B
Vaxcyte (PCVX)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.8B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.5B
Exelixis (EXEL)
$10.2B
QIAGEN (QGEN)
$10.1B
Revolution Medicines (RVMD)
$9.9B
Exact Sciences (EXAS)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$8.1B
Ascendis Pharma (ASND)
$7.7B